TPPHQ Tapestry Pharmaceuticals featured news, full reports, and detailed charts
Tapestry Pharmaceuticals (TPPHQ/TPPHQ.PK) Wrap Up:
Tapestry Pharmaceuticals, Inc., together with its subsidiaries, focuses on the development of proprietary therapies for the treatment of cancer. It also engages in evaluating new therapeutic agents and/or related technologies that involve the examination of individual molecules, classes of compounds, or platform technologies. The company provides therapeutic candidate programs, including TPI 287 IV and TIP 287 oral formulations for prostate, non-small cell lung, and other cancers. Tapestry Pharmaceuticals was founded in 1991 and is based in Boulder, Colorado. On March 19, 2009, Tapestry Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Colorado.Tapestry Pharmaceuticals (TPPHQ:OTC)
TPPHQ Top Compensated Officers
Executives, Board Directors
Key developments for Tapestry Pharmaceuticals (TPPHQ)
Effective March 23, 2009, Tapestry Pharmaceuticals will change its OTCPK stock ticker symbol to TPPHQ from TPPH.
The NASDAQ Stock Market announced that it will delist the common stock of Tapestry Pharmaceuticals, Inc. The company’s stock was suspended on April 11, 2008 and has not traded on NASDAQ since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after the Form 25 is filed.
Tapestry Pharmaceuticals announced that on April 4, 2008, Stephen K. Carter, M.D., resigned from the Board of Directors after three years of service. On April 4, 2008, the Board of Directors of the Company elected Gordon H. Link, Jr. as a director to fill the vacancy created the resignation of Dr. Stephen K. Carter. On April 4, 2008, the Board of Directors accepted the resignation of Leonard P. Shaykin as Chief Executive Officer. He remains a member of Board of Directors. On April 4, 2008, the Board of Directors appointed Gordon H. Link, Jr., age 54, as Chief Executive Officer. Mr. Link has served as Senior Vice President and Chief Financial Officer since 2002.
TPPHQ Competitors
| Company | Last | Change | |
| No competitor information is available for TPPHQ. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | TPPHQ | Industry Range |
| No financial data is available for TPPHQ. | ||
TPPHQ transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Tapestry Pharmaceuticals
More news for TPPHQ
TAPESTRY PHARMACEUTICALS, INC Financials
PERIOD ENDING26-Sep-0727-Jun-0728-Mar-0727-Dec-06Total Revenue - - - - Cost of Revenue - - - - Gross Profit - - - - Operating ExpensesResearch Development4,527 3,994 2,893 2,925 Selling General and Administrative1,736 2,399 1,776 1,904 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(6,263)(6,393)(4,669)(4,829)Income from Continuing OperationsTotal Other Income/Expenses Net169 223 270 360 Earnings Before Interest And Taxes(6,094)(6,170)(4,399)(4,469)Interest Expense6 5 7 91 Income Before Tax(6,100)(6,175)(4,406)(4,560)Income Tax Expense - - - 8 Minority Interest - - - - Net Income From Continuing Ops(6,100)(6,175)(4,406)(4,568)Non-recurring EventsDiscontinued Operations - - - 29 Extraordinary Items - - - - Effect Of Accounting Changes - - &nbs...Click here to read the whole Article (external link)
TAPESTRY PHARMACEUTICALS, INC Files SEC form 8-K, Bankruptcy or Receivership
Show all filings for TAPESTRY PHARMACEUTICALS, INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for TAPESTRY PHARMACEUTICALS, INC 25-Mar-2009Bankruptcy or Receivership Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purpose...Click here to read the whole Article (external link)